| Cas No.: | 125961-82-2 |
| Synonyms: | KCA 757,MN001,KCA757,MN-001,KCA-757 |
| SMILES: | CCCC1=C(OCCCSC2=CC=C(C(C)=O)C(O)=C2CCC)C=CC(C(C)=O)=C1OCCCC(O)=O |
| Formula: | C29H38O7S |
| M.Wt: | 530.6 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model.. For the detailed information of MN-001 (Tipelukast), the solubility of MN-001 (Tipelukast) in water, the solubility of MN-001 (Tipelukast) in DMSO, the solubility of MN-001 (Tipelukast) in PBS buffer, the animal experiment (test) of MN-001 (Tipelukast), the cell expriment (test) of MN-001 (Tipelukast), the in vivo, in vitro and clinical trial test of MN-001 (Tipelukast), the EC50, IC50,and affinity,of MN-001 (Tipelukast), Please contact DC Chemicals. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
